ESMO Immuno-Oncology 2025 | The future of bispecific checkpoint inhibitors for solid tumors
Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Hospital Universitario Quirónsalud Madrid, Madrid, Spain, highlights the rationale and interest in developing bispecific antibodies for PD-1 and CTLA-4, as well as multi-specifics, including tetra-specifics, to target various immune inhibitory signals beyond the traditional PD-(L)1 axis. While LAG-3 may pose challenges due to its association with T-cell exhaustion, it still presents opportunities for development as a biomarker or inhibitory signal. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, again, that’s a great question and actually was mentioned and discussed extensively during the SITC Congress. So there is space for development for this LAG-3 agent. I think there is rationale and potential, as we show in this trial, there is first human evidence. There is also a lot of interest in developing B-specific antibodies for PD-1 and CTLA-4. Again, I remember some of the talks first on this basis sparked a lot of interest...
Yeah, again, that’s a great question and actually was mentioned and discussed extensively during the SITC Congress. So there is space for development for this LAG-3 agent. I think there is rationale and potential, as we show in this trial, there is first human evidence. There is also a lot of interest in developing B-specific antibodies for PD-1 and CTLA-4. Again, I remember some of the talks first on this basis sparked a lot of interest. And there were other targets that, however, raised some concerns, like LAG-3, as related to probably a more profound T-cell exhaustion. So it might be more challenging to actually develop LAG-3 as a biomarker or an inhibitory signal itself in terms of immunotherapy efficacy. There is in parallel a lot of development to not just develop B-specifics, but multi-specifics. There were a number of talks even highlighting tetra-specifics, or in some, just being more efficient in targeting the different immune inhibitory signals that we have, not just based on the traditional PD-1, PD-L1 axis. So yes, I think there’s a lot of room for development in that sense.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
